Epithelial ovarian cancer
The most common type — about 90% of cases. Includes high-grade serous (the most common subtype), endometrioid, clear cell, and mucinous variants.
Ovarian Cancer Treatment in Hyderabad
Ovarian cancer is the gynaecologic cancer most often caught late — because there is no Pap-smear-equivalent screening test for the general population. The signal that matters is persistent bloating. Dr. Madhav Danthala provides treatment planning, chemotherapy, PARP inhibitors, and second opinions at Omega Hospitals, Gachibowli, and Peoples Polyclinic, Manikonda.
What is Ovarian Cancer?
Ovarian cancer is not a single disease. The biology and the BRCA/HRD status shape treatment.
BRCA-related disease
About 15-20% of ovarian cancers are linked to BRCA1 or BRCA2 mutations. These respond particularly well to PARP inhibitors as maintenance therapy.
Germ cell and stromal tumours
Less common, often in younger women. Generally curable with chemotherapy or surgery alone in early stages.
When to See a Doctor
Most causes of bloating and pelvic discomfort are benign. The pattern that matters is persistence — symptoms that are new, last more than three weeks, and happen most days.
Persistent bloating
New and ongoing abdominal bloating that does not resolve over weeks.
Pelvic or abdominal pain
Persistent pressure or pain in the lower abdomen or pelvis.
Feeling full quickly
Loss of appetite or feeling full after very small meals.
Family history concerns
First-degree relative with ovarian or breast cancer, particularly under 50 — discuss BRCA testing.
Dr. Danthala's Approach
Ovarian cancer treatment in 2026 is increasingly molecularly guided.
BRCA and HRD profiling first
Every advanced ovarian cancer should be tested for BRCA mutation and HRD status at diagnosis to identify candidates for PARP-inhibitor maintenance.
More than one path
For advanced disease, primary surgery vs neoadjuvant chemotherapy followed by interval surgery are both defensible — depending on disease spread and patient fitness.
Clear, structured communication
Every consult ends with a written summary of the plan, expected timeline, and the trade-offs each option carries.
Frequently Asked Questions
Is there a screening test for ovarian cancer?
For average-risk women, no. The Pap smear catches cervical cancer, the mammogram catches breast — but for ovarian, no equivalent test works for the general population. This is why ovarian cancer is most often caught late. For high-risk women (BRCA carriers), surveillance with TVUS and CA-125 is offered.
What are the warning signs?
Persistent bloating, pelvic or abdominal pain, feeling full quickly, and urinary urgency. The pattern that matters is when they are new, last more than three weeks, and happen most days.
Should I get BRCA testing?
BRCA1 and BRCA2 mutations significantly raise lifetime ovarian and breast cancer risk. Testing is recommended for personal or family history of breast or ovarian cancer (especially before age 50), male breast cancer in the family, or known BRCA mutation in a relative.
What is a PARP inhibitor?
PARP inhibitors (olaparib, niraparib, rucaparib) are oral targeted therapies particularly effective in BRCA-mutated or HRD-positive ovarian cancers. Used as maintenance therapy after chemotherapy. Significantly improve outcomes for selected patients.
What does treatment usually involve?
Surgery (debulking) combined with platinum-based chemotherapy. Order depends on tumour spread and patient fitness. Maintenance with PARP inhibitors or anti-VEGF agents is often added based on molecular profile.
Consult Dr. Madhav Danthala
For first opinion, second opinion, or treatment planning: